Recombinant 2019-nCoV Guanine-N7_meth (N-6His)
Recombinant 2019-nCoV Guanine-N7_meth (N-6His) from ELK Biotechnology Read more ›
Product Description
Recombinant 2019-nCoV Guanine-N7_meth (N-6His) is an ELK Biotechnology recombinant protein for research use.
Description
Recombinant 2019-nCoV Guanine-N7 methyltransferase is produced by our E.coli expression system and the target gene encoding Ala1-Gln527 is expressed with a 6His tag at the N-terminus.
Background
The nonstructural protein (nsp) 14 of SARS-CoV 2 was identified as a cap (guanine-N7)-methyltransferase (N7-MTase). Nsp14 of coronaviruses two different activities: an exoribonuclease activity acting on both ssRNA and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase activity. It may be involved in the proof-reading ability during the viral RNA replication and transcription. GTP, dGTP as well as cap analogs GpppG, GpppA and m7GpppG could be methylated by nsp14.
Handling information
| Delivery condition | The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below. |
|---|
Key Facts
| Target | Recombinant 2019-nCoV Guanine-N7_meth |
| Also known as | SARS-CoV 2 nsp14; SARS-CoV 2 ExoN; Guanine-N7 methyltransferase |
| Purity | Greater than 85% as determined by reducing SDS-PAGE. |
| Form / buffer | Lyophilized protein |
| Research area | Infectious Diseases, Molecular Biology |
| Specification | PURITY | ENDOTOXIN | BIOACTIVITY |
|---|---|---|---|
| Product QC |
Specifications
Storage & Stability
Compliance & Certifications
Manufactured under ISO 9001:2015 quality management standards.
Not intended for diagnostic or therapeutic use.